Vnitr Lek 2005, 51(7-8):826-832

Antiaggregant therapy

J. Malý^*, M. Pecka, P. Dulíček, M. Blažek, L. Smolej

II. interní klinika Lékařské fakulty UK a FN, Hradec Králové, přednosta prof. MUDr. Jaroslav Malý, CSc.

Antiaggregant treatment is suitable for all at risk patients with atherothrombosis and its cardiovascular complications. Antiaggregant treatment decreases severe vascular events in at risk patients, myocardial infarctions, non-fatal strokes, transient ischaemic attacks, unstable angina, obstructive peripheral vascular disease. It decreases a risk of embolism caused by atrial fibrillation and a risk of vascular occlusion in other patients at high risk. Antiaggregant treatment should be administered long-term. The basic antiaggregant drug is acetylsalicylic acid (ASA) which is commonly used in doses of 75-150 mg daily. Acetylsalicylic acid is an effective antiaggregant drug with clearly demonstrated beneficial effect on atherothrombotic complications in cardiovascular diseases. Other substances and drugs with antiaggregant effect including their modes of action and indications are reviewed.

Keywords: cardiovascular diseases; antiaggregant therapy

Received: March 11, 2005; Accepted: March 11, 2005; Published: July 1, 2005  Show citation